Avidity Biosciences Inc

-0.10 (-0.67%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)699.21M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.18 Million
Adjusted EPS-$0.70
See more estimates
10-Day MA$16.05
50-Day MA$22.24
200-Day MA$22.52
See more pivots

Avidity Biosciences Inc Stock, NASDAQ:RNA

10975 North Torrey Pines Road, Suite 150, La Jolla, California 92037
United States of America
Phone: +1.858.401.7900
Number of Employees: 82


Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in La Jolla, CA.